Clinical assessment of human gonadotrophins produced by recombinant DNA technology

Loumaye, Ernest; Martineau, Isabelle; Piazzi, Angela; O’Dea, Louis; Ince, Susan; Howles, Colin M.; Decosterd, Genevieve; Loon, Katherine Van; Galazka, Andrew

doi:10.1093/humrep/11.suppl_5.95

Cited by 44 publications

(32 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently recombinant hormones have also been developed with a similar activity profile. 105 Deglycosylated hCG has been described as an antagonist of the LH receptor. 106 Recently, another hormonal antagonist was identified, which was generated by fusing two hCG b-subunits.…”

Section: L H R E C E P T O R a G O N I S T Smentioning

confidence: 99%

“…Urinary and recombinant FSH is also used in the treatment of infertility. 105 Recombinant gonadotropins need to be administered daily and therefore effort was made to develop gonadotropins with a longer half-life. Long-acting FSH may be produced by fusing the carboxyl terminal extension of the b-subunit of hCG to the b-subunit of FSH or by additional glycosylation of FSH.…”

Section: F S H R E C E P T O R L I G a N D Smentioning

confidence: 99%

See 1 more Smart Citation

G protein‐coupled receptors of the hypothalamic–pituitary–gonadal axis: A case for gnrh, LH, FSH, and GPR54 receptor ligands

Heitman

IJzerman

2008

Medicinal Research Reviews

View full text Add to dashboard Cite

The hypothalamic-pituitary-gonadal (HPG) axis, important in reproduction and sex hormone-dependent diseases, is regulated by a number of G protein-coupled receptors. The recently "deorphanized" GPR54 receptor activated by the peptide metastin is thought to be the key regulator of the axis, mainly by releasing gonadotropin-releasing hormone (GnRH) from the hypothalamus. The latter decapeptide, through the activation of the GnRH receptor in the anterior pituitary, causes the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which subsequently activate their respective receptors on the gonadotrope cells. In this review we will discuss the small molecule agonists and antagonists that are currently being developed to intervene with the action of these four receptors. For GnRH receptors, 14 different chemical classes of non-peptidic antagonists have been reported, while for the LH receptor three classes of agonists have been described. Both agonists and antagonists have been introduced for the FSH receptor. Recently, the first non-peptidic agonist for GPR54 was reported.

show abstract

Section: L H R E C E P T O R a G O N I S T Smentioning

confidence: 99%

Section: F S H R E C E P T O R L I G a N D Smentioning

confidence: 99%

G protein‐coupled receptors of the hypothalamic–pituitary–gonadal axis: A case for gnrh, LH, FSH, and GPR54 receptor ligands

Heitman

IJzerman

2008

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Subcutaneous rhCG has been recently introduced for final follicular maturation and ovulation induction in infertile women undergoing ART. rhCG preparations are derived from genetically engineered Chinese hamster ovary cells through recombinant DNA technology [5]. This product is purified by repeated chromatographic steps to produce a high specific activity outcome which makes the drug free from urinary contaminations and suitable for subcutaneous injection and self administration with lower local reactions and higher tolerability [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial

Madani

Yeganeh

Ezabadi

et al. 2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To compare the number of oocytes per follicles in ovulation induction with 10,000 IU urinary hCG (uhCG) and two different doses of recombinant hCG (rhCG) in women undergoing intracytoplasmic sperm injection (ICSI) cycles. Methods This study was a prospective, randomized controlled trial which was performed on 180 primary infertile women undergoing ICSI cycles. All eligible patients underwent a standard GnRH-a long protocol. When at least two follicles reached a diameter of 18 mm, all patients were randomized to receive 10,000 IU urinary hCG or 250 μg recombinant hCG or 500 μg recombinant hCG for ovulation induction. Primary outcome measure included the number of oocytes retrieved per aspirated follicles. Secondary outcome measures were the number of oocytes retrieved, the number of mature oocytes, the number and quality of generated embryos, fertilization rate, implantation rate, chemical and clinical pregnancy rates and OHSS occurrence rate. Results The mean number of retrieved oocytes per follicles were 71.82 ± 15.09, 69.84 ± 17.44 and 77.16 ± 17.61 in 10,000 IU uhCG, 250 μg rhCG and 500 μg rhCG, respectively which was significantly higher with 500 μg rhCG than the lower dose(P=.04). Other cycles and clinical outcomes were comparable between groups. Conclusion Recombinant hCG shows equivalent efficacy to urinary hCG in terms of the number of oocytes per aspirated follicles in selected patients undergoing ICSI; however, 500 μg rhCG seems to be more advantageous than the lower dose in this indication. Larger randomized trials are needed to generalize this strategy.ClinicalTrials.gov identifier: NCT01507376.

show abstract

“…The consulting physician was blinded as to the randomization arm of the patient, and all the patients gave their signed informed consent. Inclusion criteria were: [1] female age <36 years, [2] rank trial %2, [3] FSH on day 3 of the cycle %12 IU/mL, [4] male or tubal infertility, and [5] one embryo (n ¼ 1) at the blastocyst stage to be transferred in each group. The primary outcome was the blastulation rate.…”

mentioning

confidence: 99%

Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in single-blastocyst IVF antagonist cycles: a randomized controlled trial

Papanikolaou¹,

Fatemi²,

Camus³

et al. 2010

Fertility and Sterility

View full text Add to dashboard Cite

Clinical assessment of human gonadotrophins produced by recombinant DNA technology

Cited by 44 publications

References 30 publications

G protein‐coupled receptors of the hypothalamic–pituitary–gonadal axis: A case for gnrh, LH, FSH, and GPR54 receptor ligands

G protein‐coupled receptors of the hypothalamic–pituitary–gonadal axis: A case for gnrh, LH, FSH, and GPR54 receptor ligands

Comparing the efficacy of urinary and recombinant hCG on oocyte/follicle ratio to trigger ovulation in women undergoing intracytoplasmic sperm injection cycles: a randomized controlled trial

Higher birth rate after recombinant hCG triggering compared with urinary-derived hCG in single-blastocyst IVF antagonist cycles: a randomized controlled trial

Contact Info

Product

Resources

About